What is the survival rate for lenvatinib?

medsforcancer

Lenvatinib is a tyrosine kinase inhibitor (TKI) used to treat various cancers, including hepatocellular carcinoma (HCC), thyroid cancer, and renal cell carcinoma (RCC). The survival rate for patients taking lenvatinib depends on the type and stage of cancer, previous treatments, and overall patient health. Clinical studies have provided valuable insights into its effectiveness and impact on survival.

Survival Rates in Hepatocellular Carcinoma (HCC)
Lenvatinib is approved for first-line treatment of unresectable HCC and is often compared to sorafenib, the previous standard treatment. The REFLECT trial, a pivotal phase 3 study, demonstrated that lenvatinib had a median overall survival (OS) of 13.6 months, compared to 12.3 months with sorafenib. While the difference was not statistically significant, lenvatinib showed improved progression-free survival (PFS) and objective response rate (ORR). The one-year survival rate for patients on lenvatinib was approximately 52-55%.

Survival in Differentiated Thyroid Cancer (DTC)
Lenvatinib is used in patients with radioiodine-refractory differentiated thyroid Lenvaxen-Lenvatinib (4/10)mg cancer (RR-DTC). The SELECT trial reported that lenvatinib significantly improved progression-free survival, with a median PFS of 18.3 months versus 3.6 months in the placebo group. The median overall survival was not reached at the time of analysis, but estimated rates suggested prolonged survival benefits. The two-year survival rate was over 80%, reflecting the drug’s strong efficacy in this cancer type.

Survival in Renal Cell Carcinoma (RCC)
For RCC, lenvatinib is typically used in combination with other agents, such as everolimus or pembrolizumab. In a study comparing lenvatinib plus everolimus to everolimus alone, the combination therapy improved median OS to 25.5 months versus 15.4 months. When combined with pembrolizumab, the median OS had not been reached at the time of analysis, but early data suggested a 40% reduction in the risk of death compared to sunitinib.

Factors Influencing Survival Rates
Survival outcomes vary based on multiple factors:

Cancer Type and Stage – Advanced-stage cancers tend to have lower survival rates.
Combination Therapies – Lenvatinib often performs better when combined with immunotherapies.
Patient Health and Tolerance – Some patients discontinue due to side effects like hypertension, fatigue, and diarrhea.
Biomarkers and Tumor Characteristics – Certain genetic mutations influence how well a patient responds to lenvatinib.

Conclusion
Lenvatinib has demonstrated significant survival benefits across different cancer types. While it may not always drastically extend overall survival, it improves progression-free survival and response rates. The survival rate varies widely depending on individual patient factors, but in general, one-year survival rates range from 52% in HCC to over 80% in thyroid cancer, with renal cell carcinoma patients also showing favorable outcomes. The continued use of combination therapies is likely to further improve these survival statistics in the future.